ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 249

Where to Look for Uric Acid Crystals? Results from a Norwegian Ultrasound Study

Hilde B Hammer1, Lars Karoliussen2, Lene Terslev3, Espen A. Haavardsholm4, Tore K Kvien5 and Till Uhlig4, 1Rheumatology, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 4Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5On behalf of the NOR-DMARD registry, Oslo, Norway

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Crystal-induced arthritis, gout and ultrasound

Session Information

Date: Sunday, November 5, 2017

Title: Imaging of Rheumatic Diseases Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Ultrasound (US) has received an increasing attention in detecting uric monosodium urate (MSU) deposits, and is included in the ACR/EULAR classification criteria for gout. The OMERACT US group has developed definitions for US elementary lesions in gout including double contour (DC) sign (deposits of crystals on the surface of cartilage), tophus (larger hypo-echoic aggregation of crystals, usually well delineated), aggregates (small hyper-echoic deposits) and erosions. MSU deposits may be found in many different regions in an individual with gout but with some predilection sites. The present objective was to asses by US the presence of MSU deposits in a high number of locations known to be involved, and to identify areas to include when screening for gout by US.

Methods:

This includes baseline data from a prospective observational study where patients with crystal-proven gout who presented after a recent gout flare were included (117 patients (mean (SD) 56.9 (14.1) years old, 8.5 (7.3) years disease duration, 93.2% men), all with insufficiently treated serum uric acid level (>360 μmol/L/>6 mg/dl). We performed a systematic extensive assessment with US (GE E9 machine, grey scale 15MHz) to detect MSU deposits, using the OMERACT definitions for DC, tophi and aggregates. The following locations were assessed bilaterally; radiocarpal joint, MCP 2, insertion of triceps and quadriceps, the patellar tendon (divided into proximal and distal), cartilage of distal femur (maximal flexed knee) and the talar cartilage of the tibiotalar joint, the MTP 1 joint as well as the Achilles tendon. Sum of sites with deposits was calculated and correlations were performed by use of Spearman, and frequencies of deposits were calculated as percentages at each site.

Results:

The mean (SD) serum uric acid level was 488 (88) μmol/L. There was no significant correlation between number of sites with deposits and uric acid level (r=0.11), but with disease duration (r=0.25, p=0.007). The table shows that DC was primarily found in MTP1, followed by talar and femoral cartilage. Tophi and aggregates were primarily found in MTP1, followed by distal patellar and triceps tendons. There were no major differences between right and left side. In 21 patients (17.9%) DC was seen on femoral or talar cartilage, but not in the MTP1 joints.

Conclusion:

There is limited knowledge on the primary locations of MSU deposits, and the present study suggests US examinations of MTP1, distal patellar and triceps tendons as well as talar and femoral cartilage to be the most important sites to explore for presence of MSU deposits in patients examined for possible gout.

Double contour

Tophus

Aggregates

Right

Left

Right

Left

Right

Left

Wrist

1.7

0

7.7

9.5

7.7

8.6

MCP 2

0

0

3.5

1.8

2.6

1.7

Distal femur cartilage

15.3

16.1

NA

NA

NA

NA

Talar cartilage

18.8

19.7

NA

NA

NA

NA

MTP 1

36.2

32.5

44.0

45.7

46.5

53.0

Triceps

NA

NA

18.0

14.5

29.1

30.8

Quadriceps

NA

NA

6.0

11.9

10.3

19.7

Proximal patellar tendon

NA

NA

4.3

7.7

10.4

12.0

Distal patellar tendon

NA

NA

22.4

17.1

42.2

39.3

Achilles

NA

NA

8.7

8.7

11.3

6.1


Disclosure: H. B. Hammer, AbbVie Norway, 2,Abbvie, 8,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 8,Roche Pharmaceuticals, 8; L. Karoliussen, None; L. Terslev, None; E. A. Haavardsholm, None; T. K. Kvien, AbbVie, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,UCB, 2,BMS, 2,MSD, 2,AbbVie, 5,Pfizer Inc, 5,BMS, 8,MSD, 8,Roche Pharmaceuticals, 8,UCB, 8,AbbVie, 8; T. Uhlig, None.

To cite this abstract in AMA style:

Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Where to Look for Uric Acid Crystals? Results from a Norwegian Ultrasound Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/where-to-look-for-uric-acid-crystals-results-from-a-norwegian-ultrasound-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/where-to-look-for-uric-acid-crystals-results-from-a-norwegian-ultrasound-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology